Work

Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Year: 2013

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-13-0427

Authors: Cristiana Sessa, Patricia Lorusso, Anthony Tolcher, Françoise Farace, Nathalie Lassau, Angelo Delmonte, Antonio Braghetti, Rastislav Bahleda, Patrick Cohen, Marie Hospitel, Christine Veyrat-Follet, Jean-Charles Soria

Institutions: Institut Gustave Roussy, The Barbara Ann Karmanos Cancer Institute, Istituto Oncologico della Svizzera Italiana

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Sanofi

OpenAlex ID: W2015261814

FWCI: 2.561

Cites: 36

Cited by: 46

Related to: 10